Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ghrelin treatment of comatose patients after cardiac arrest
2018-000005-23Phase 2Active
- Sponsor
- University of Twente
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of acyl-ghrelin in hypoxic-ischemic encephalopathy (HIE), sponsored by University of Twente. Primary endpoint: Functional outcome at 6 months (CPC). Started Nov 2018; status: active.
02
Drugs
acyl-ghrelin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on 2018-000005-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000005-23.